Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.
about
Interventions for the management of oral ulcers in Behçet's diseaseInterventions for the management of oral ulcers in Behçet's diseaseBehçet's disease: a new target for anti-tumour necrosis factor treatmentBehçet's diseaseIntestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future PerspectivesBehçet's disease in children, an overviewHereditary auto-inflammatory disorders and biologicsA double-blind trial of depot corticosteroids in Behçet's syndromeThalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's diseaseConcurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography.Gender Differences in Behçet's Disease Associated Uveitis.Behçet's disease: an update.Immunomodulation by thalidomide and thalidomide analoguesBiological treatments in Behçet's disease: beyond anti-TNF therapy.Perspective on future therapy of vasculitis.The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.Efficacy of tumour necrosis factor-α antagonists in aphthous ulceration: review of published individual patient data.Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma.Update on therapy--thalidomide in the treatment of lupus.The multiple faces of Behçet's disease and its aetiological factors.Thalidomide: dual benefits in palliative medicine and oncology.Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51The treatment of chronic recurrent oral aphthous ulcers.Novel therapies in vasculitis.Number VII Behçet's disease (Adamantiades syndrome).Behçet's disease: immunopathologic and therapeutic aspects.Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.Thalidomide use in pediatric patients.Small therapeutic molecules for the treatment of inflammatory bowel diseaseIntravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.Thalidomide: an old drug with new clinical applications.Treatment of neuro-Behçet's disease: an update.Thalidomide in dermatology.Thalidomide in multiple myeloma--from the clinic to the laboratory.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.Thalidomide and its derivatives: emerging from the wilderness.Dermatologic and nondermatologic uses of thalidomide.Thalidomide in dermatology: revisited.
P2860
Q24193450-D280E599-6489-408B-A867-C3798AF5B7CAQ24198926-056775DE-D871-409E-8F13-EE61048C3013Q24675071-D76C5128-EB91-4FB4-8B3C-196449C21867Q24804631-7AB1B246-8AC0-4A9A-BB7D-2B7518903A78Q26775240-1F78746D-02D5-4C48-857B-EB191A075E75Q26799767-444E63A0-A1D6-4125-BAE6-14050B46FA02Q28069448-90D75719-0B1E-4E23-93AD-5CBDC6566ECFQ28243289-0B17EED5-70DD-47FB-B3AD-BAFAC22BCC44Q28279953-BC6A9796-5E0E-46D6-BC52-642DB2C4C498Q28344943-B3D27470-768F-4964-AA46-B6FA3A8AD6BFQ33210899-3C47AC33-62E4-49CD-8088-0CBC1F9F1793Q33597470-9398FF3E-B164-4034-A813-8368D9D9E745Q33647315-11ECEF10-79CF-48E5-95F3-BDD804B2518EQ33782386-73EACBF9-0CBE-450E-A5DC-F726B5554D78Q33908217-7E6C1192-F90B-4291-81FD-C109FEB50254Q34109103-9FE9C779-DDEB-4BBD-A9A9-2B688DBBDD78Q34109142-55FFE471-5BDC-493B-85A2-DF46569742B4Q34142185-728791A9-6D36-4044-BB87-FA7C177B497CQ34193973-9A67C8B0-2D00-4E15-B9CA-56415DC42E3EQ34227018-9FAA0EBE-E5A1-490E-B4C1-A5669EF72AC8Q34331350-40777293-CD4E-4F86-96CC-298ED07A31D5Q34375023-0F1565BE-8FCE-4193-AECB-7D5CB089ACDDQ34402273-1D966554-F090-4710-B59B-5B2674C77C4AQ34430267-9B07A916-BE35-4FB3-B8B5-FDB027FBF25DQ34481560-432341D0-82C3-446B-A1CD-78997286D60FQ34494125-A0C7CA6E-544D-4E00-99AB-6B48EB143564Q34499535-07ADB9AA-E07C-4EBF-A11F-E5AEC84020A4Q34505540-1D2AD3DE-6DFB-46A2-BEBC-DA7B4027D81FQ34564331-A3EC2ED0-0E41-4EDD-AF99-1CAE0C51C6FFQ34600992-A8EE015B-EF5A-4638-883E-7DE9652B31C0Q34646752-19D4F55A-827C-458E-98B0-D2FCF77A0C30Q34798767-3A92A5AA-45A8-4BBE-8AB2-B7FC66BFDCA0Q34974052-F3872F86-B110-497B-8E86-7680BFC80EC4Q34992495-6288126C-5882-470D-AD4A-91F2201BBFB1Q35008319-750E6DA3-C4F6-4026-A004-9A5E49DFF7B7Q35026302-91039085-B992-4792-89BA-270B9C0D4762Q35062816-E83A819D-DE31-4C44-8626-B7D08FB2BF9EQ35107977-7A43F537-1E22-4A4F-A3E3-952598477E09Q35201057-8475B794-0F6C-4F7E-B343-60F63EC54583Q35215252-72ED2056-1AF0-4691-8254-BD5B51D59441
P2860
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@ast
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@en
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@nl
type
label
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@ast
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@en
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@nl
prefLabel
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@ast
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@en
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@nl
P2093
P921
P1476
Thalidomide in the treatment o ...... ind, placebo-controlled trial.
@en
P2093
Hamuryudan V
Ozyazgan Y
Yurdakul S
Zwingenberger K
P304
P356
10.7326/0003-4819-128-6-199803150-00004
P407
P577
1998-03-01T00:00:00Z